Provided by Tiger Trade Technology Pte. Ltd.

crane

197.57
+2.121.08%
Volume:47.33K
Turnover:9.37M
Market Cap:11.38B
PE:34.48
High:199.00
Open:197.87
Low:197.16
Close:195.45
52wk High:230.50
52wk Low:159.58
Shares:57.60M
Float Shares:48.76M
Volume Ratio:1.14
T/O Rate:0.10%
Dividend:0.98
Dividend Rate:0.49%
EPS(TTM):5.73
EPS(LYR):6.26
ROE:16.52%
ROA:12.73%
PB:5.23
PE(LYR):31.58

Loading ...

Honda Recalls Over One Million Vehicles in the U.S., Primarily Affecting CR-V and Accord Hybrid Models

Deep News
·
Jun 11

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

GlobeNewswire
·
Jun 11

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

GlobeNewswire
·
Jun 11

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

GlobeNewswire
·
Jun 11

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

GlobeNewswire
·
Jun 11

Crane NXT unit Antares Vision debuts laser spectroscopy leak detection tech at ProPak Asia

Reuters
·
Jun 09

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

GlobeNewswire
·
Jun 03

Crane Is Maintained at Buy by DA Davidson

Dow Jones
·
Jun 02

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

GlobeNewswire
·
Jun 01

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

GlobeNewswire
·
Jun 01

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

GlobeNewswire
·
May 29

PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

prnewswire
·
May 28

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

GlobeNewswire
·
May 22

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

GlobeNewswire
·
May 22

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

GlobeNewswire
·
May 22

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

GlobeNewswire
·
May 22

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

GlobeNewswire
·
May 21

Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 15

Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31st, 2026

Dow Jones
·
May 14

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

GlobeNewswire
·
May 14